Risk factor analysis for survival at relapse among 75 patients with relapsed BL/B-AL diagnosed between 2001 and 2016: Cox regression analysis
| Characteristics . | HR (95% CI) . | P . |
|---|---|---|
| Time of relapse (after initial therapy) | 0.55 (0.29-1.02) | .058 |
| Initial therapy branch (R3/4) | 2.69 (1.1-6.5) | .027 |
| Rituximab front-line | 1.86 (0.82-4.22) | .14 |
| No rituximab in relapse | 0.79 (0.40-1.58) | .52 |
| Reinduction regimen (VICI) | 0.24 (0.09-0.64) | .004 |
| Characteristics . | HR (95% CI) . | P . |
|---|---|---|
| Time of relapse (after initial therapy) | 0.55 (0.29-1.02) | .058 |
| Initial therapy branch (R3/4) | 2.69 (1.1-6.5) | .027 |
| Rituximab front-line | 1.86 (0.82-4.22) | .14 |
| No rituximab in relapse | 0.79 (0.40-1.58) | .52 |
| Reinduction regimen (VICI) | 0.24 (0.09-0.64) | .004 |